Literature DB >> 1548249

Possible trazodone potentiation of fluoxetine: a case series.

A A Nierenberg1, J O Cole, L Glass.   

Abstract

BACKGROUND: Fluoxetine is an effective serotonin reuptake inhibitor antidepressant that can fail to alleviate either insomnia or major depression in a substantial minority of depressed patients. Trazodone has been reported to be both an effective nonbenzodiazepine hypnotic for antidepressant-associated insomnia and a possible serotonergic antidepressant adjunct. We present a case series of patients with variable responses when trazodone was added to fluoxetine.
METHOD: Eight consecutive depressed (DSM-III-R) patients taking fluoxetine were given trazodone either for sleep or as a possible antidepressant potentiator.
RESULTS: Three (37.5%) of the eight patients (confidence interval = 4.0%-71.0%) had improvements in both sleep and depression. The remaining five patients either were unaffected by the addition of trazodone to fluoxetine or had intolerable adverse drug reactions.
CONCLUSION: Trazodone may be an effective hypnotic and antidepressant potentiator when combined with fluoxetine for some patients, but its use may be limited by adverse effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548249

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 3.  Update on augmentation of antidepressant response in resistant depression.

Authors:  Charles DeBattista; Anna Lembke
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

Review 4.  Rediscovering trazodone for the treatment of major depressive disorder.

Authors:  Andrea Fagiolini; Alessandro Comandini; Mario Catena Dell'Osso; Siegfried Kasper
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

5.  Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial.

Authors:  Charles M Morin; Jack D Edinger; Andrew D Krystal; Daniel J Buysse; Simon Beaulieu-Bonneau; Hans Ivers
Journal:  Trials       Date:  2016-03-03       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.